Literature DB >> 16306938

An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection.

Deborah Palliser1, Dipanjan Chowdhury, Qing-Yin Wang, Sandra J Lee, Roderick T Bronson, David M Knipe, Judy Lieberman.   

Abstract

Herpes simplex virus 2 (HSV-2) infection causes significant morbidity and is an important cofactor for the transmission of HIV infection. A microbicide to prevent sexual transmission of HSV-2 would contribute substantially to controlling the spread of HIV and other infections. Because RNA interference (RNAi) provides effective antiviral defence in plants and other organisms, several studies have focused on harnessing RNAi to inhibit viral infection. Here we show that vaginal instillation of small interfering RNAs (siRNAs) targeting HSV-2 protects mice from lethal infection. siRNAs mixed with lipid are efficiently taken up by epithelial and lamina propria cells and silence gene expression in the mouse vagina and ectocervix for at least nine days. Intravaginal application of siRNAs targeting the HSV-2 UL27 and UL29 genes (which encode an envelope glycoprotein and a DNA binding protein, respectively) was well tolerated, did not induce interferon-responsive genes or cause inflammation, and protected mice when administered before and/or after lethal HSV-2 challenge. These results suggest that siRNAs are attractive candidates for the active component of a microbicide designed to prevent viral infection or transmission.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16306938     DOI: 10.1038/nature04263

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  132 in total

1.  SPANosomes as delivery vehicles for small interfering RNA (siRNA).

Authors:  Chenguang Zhou; Yicheng Mao; Yasuro Sugimoto; Yue Zhang; Naveen Kanthamneni; Bo Yu; Robert W Brueggemeier; L James Lee; Robert J Lee
Journal:  Mol Pharm       Date:  2011-12-29       Impact factor: 4.939

2.  Design and assembly of new nonviral RNAi delivery agents by microwave-assisted quaternization (MAQ) of tertiary amines.

Authors:  Animesh Ghosh; Koushik Mukherjee; Xinpeng Jiang; Ying Zhou; Joshua McCarroll; James Qu; Pamela M Swain; Huricha Baigude; Tariq M Rana
Journal:  Bioconjug Chem       Date:  2010-09-15       Impact factor: 4.774

Review 3.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

4.  Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency.

Authors:  Isaure du Chéné; Euguenia Basyuk; Yea-Lih Lin; Robinson Triboulet; Anna Knezevich; Christine Chable-Bessia; Clement Mettling; Vincent Baillat; Jacques Reynes; Pierre Corbeau; Edouard Bertrand; Alessandro Marcello; Stephane Emiliani; Rosemary Kiernan; Monsef Benkirane
Journal:  EMBO J       Date:  2007-01-24       Impact factor: 11.598

Review 5.  Decompartmentalizing target validation-thinking outside the pipeline boxes.

Authors:  Rob Hooft van Huijsduijnen; Christian Rommel
Journal:  J Mol Med (Berl)       Date:  2006-08-05       Impact factor: 4.599

6.  Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus.

Authors:  Stefanie Müller; Stephan Günther
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

7.  Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo.

Authors:  Angela A Alexander-Bryant; Anca Dumitriu; Christopher C Attaway; Hong Yu; Andrew Jakymiw
Journal:  J Control Release       Date:  2015-09-18       Impact factor: 9.776

8.  Amelioration of colorectal cancer using negative lipidoid nanoparticles to encapsulate siRNA against APRIL by enema delivery mode.

Authors:  Weifeng Ding; Guihua Wang; Keke Shao; Feng Wang; Hua Huang; Shaoqing Ju; Hui Cong; Huimin Wang
Journal:  Pathol Oncol Res       Date:  2014-04-26       Impact factor: 3.201

9.  Nanotubes functionalized with lipids and natural amino acid dendrimers: a new strategy to create nanomaterials for delivering systemic RNAi.

Authors:  Joshua McCarroll; Huricha Baigude; Chao-Shun Yang; Tariq M Rana
Journal:  Bioconjug Chem       Date:  2010-01       Impact factor: 4.774

Review 10.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.